Aurenar Secures $5.7 Million in Latest Seed Funding Round

Aurenar secured $5.7 million in its latest Seed, adding another data point to the Healthcare & Life Sciences funding market.

Aurenar Raises $5.7 million in Funding

Aurenar Closes Oversubscribed $5.7M Seed Round Led by the Go Red for Women Venture Fund™ and Solas BioVentures. Aurenar's V-Link™ platform, which recently received breakthrough device designation from the FDA, delivers transauricular vagus nerve stimulation (taVNS) to modulate the body's inflammatory response to such conditions as subarachnoid hemorrhage (SAH).

Investors Behind the Funding

The round was backed by the Go Red for Women Venture Fund™. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Aurenar operates in Healthcare & Life Sciences. Aurenar's financing adds to recent private-market activity.

Strategic Use of Funds

Transform the arc of stroke care in ICUs ST.

Looking Ahead

said Tracy Warren, Sr. Managing Director, Go Red for Women Venture Fund, part of the American Heart Association Ventures family of funds.

Source reference: original announcement/article.